share_log

Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $3

Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $3

查丹資本維持對Vincerx Pharma的買入,將目標價下調至3美元
Benzinga Real-time News ·  2022/11/17 05:01

Chardan Capital analyst Matthew Barcus maintains Vincerx Pharma (NASDAQ:VINC) with a Buy and lowers the price target from $4 to $3.

Chardan Capital分析師馬修·巴庫斯維持Vincerx Pharma(納斯達克:VNC)的買入,並將目標價從4美元下調至3美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論